Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies.
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Blood phosphorylated tau (p-tau) biomarkers, at differing sites, demonstrate high accuracy to detect Alzheimerʼs disease (AD). However, knowledge on the optimal marker for disease identification across the AD continuum and the link to pathology is limited. This is partly due to heterogeneity in analytical methods. In this study, we employed an immunoprecipitation mass spectrometry method to simultaneously quantify six phosphorylated (p-tau181, p-tau199, p-tau202, p-tau205, p-tau217 and p-tau231) and two non-phosphorylated plasma tau peptides in a total of 214 participants from the Paris Lariboisière and Translational Biomarkers of Aging and Dementia cohorts. Our results indicate that p-tau217, p-tau231 and p-tau205 are the plasma tau forms that best reflect AD-related brain changes, although with distinct emergences along the disease course and correlations with AD features—amyloid and tau. These findings support the differential association of blood p-tau variants with AD pathology, and our method offers a potential tool for disease staging in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







![Extended Data Fig. 4 Plasma tau species across Amyloid PET quartiles in Cohort 2. Box plots of plasma p-tau181, tau212-221, p-tau217, p-tau199, p-tau202, tau195-209 and p-tau231 levels in relation to amyloid PET (n=51). Participants were grouped in quartiles according to their levels of amyloid PET uptake (Q1=(-Inf,1.29]; Q2=(1.29,1.7]; Q3=(1.7,2.45]; Q4=(2.45, Inf]). The boxplots depict the median (horizontal bar), 25th to 75th percentiles (hinges) and whiskers indicate 10th and 90th percentiles. Statistical analysis across groups was performed using ANOVA (two-sided) and Tukey Contrasts were used to account for multiple comparisons (*P<0.05, **P<0.01, ***P<0.001). Exact significant p-values: P-tau181 PQ1 vs Q4 =0.0118; P-tau205 PQ1 vs Q4 <0.001, PQ2 vs Q4 <0.001, PQ3 vs Q4 = 0.0015; P-tau217 PQ1 vs Q4 <0.001, PQ2 vs Q4 <0.001, PQ3 vs Q4 <0.001; P-tau231 PQ1 vs Q4 <0.001, PQ2 vs Q4 = 0.0029, PQ3 vs Q4 = 0.0095.](https://figures.cochat.ai/paper-figures/55426e45a8b94b56a36b8643d2602c5b/mass-spectrometric-simultaneous-quantification-of-tau-species-in-plasma-shows-figure-8.jpg)






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Among proposed blood tau biomarkers,18,19,20,21 phosphorylated tau at threonine 217 (p-tau217) has consistently shown high performance in differentiating AD from other neurodegenerative disorders10,22 and in detecting AD pathology in patients with mild cognitive impairment (MCI).22”
From Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology (2024) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172
Palmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603
Self-citationKarikari, T. K., Pascoal, T. A., Ashton, N. J., Janelidze, S., Benedet, A. L., Rodriguez, J. L., Chamoun, M., Savard, M., Kang, M. S., Therriault, J., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30071-5 · Cited by 1,316
Self-citationPlasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology.
Ashton, N. J., Pascoal, T. A., Karikari, T. K., Benedet, A. L., Lantero-Rodriguez, J., Brinkmalm, G., Snellman, A., Schöll, M., Troakes, C., Hye, A., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02275-6 · Cited by 719
Self-citationthe Dominantly Inherited Alzheimer Network, Barthélemy, N. R., Li, Y., Joseph-Mathurin, N., Gordon, B. A., Hassenstab, J., Benzinger, T. L. S., Buckles, V., Fagan, A. M., Perrin, R. J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0781-z · Cited by 651
Hansson, O., Edelmayer, R. M., Boxer, A. L., Carrillo, M. C., Mielke, M. M., Rabinovici, G. D., Salloway, S., Sperling, R., Zetterberg, H., & Teunissen, C. E. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12756 · Cited by 607
Self-citationHead-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease
Janelidze, S., Bali, D., Ashton, N. J., Barthélemy, N. R., Vanbrabant, J., Stoops, E., Vanmechelen, E., He, Y., Dolado, A. O., Triana-Baltzer, G., et al. (2023) · Brain · doi:10.1093/brain/awac333 · Cited by 522
Self-citation
Cited by
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Jack, C. R., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., Hansson, O., Ho, C., Jagust, W., McDade, E., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13859 · Cited by 2,803
Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology
Ashton, N. J., Brum, W. S., Di Molfetta, G., Benedet, A. L., Arslan, B., Jonaitis, E., Langhough, R. E., Cody, K., Wilson, R., Carlsson, C. M., et al. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2023.5319 · Cited by 884
Self-citationBrum, W. S., Cullen, N. C., Janelidze, S., Ashton, N. J., Zimmer, E. R., Therriault, J., Benedet, A. L., Rahmouni, N., Tissot, C., Stevenson, J., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00471-5 · Cited by 248
Self-citationBiomarker-based staging of Alzheimer disease: rationale and clinical applications
Therriault, J., Schindler, S. E., Salvadó, G., Pascoal, T. A., Benedet, A. L., Ashton, N. J., Karikari, T. K., Apostolova, L., Murray, M. E., Verberk, I., et al. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00942-2 · Cited by 197
Self-citationChallenges in the practical implementation of blood biomarkers for Alzheimer’s disease
Schöll, M., Verberk, I. M. W., del Campo, M., Delaby, C., Therriault, J., Chong, J. R., Palmqvist, S., & Alcolea, D. A. (2024) · The Lancet Healthy Longevity · doi:10.1016/j.lanhl.2024.07.013 · Cited by 162
Metadata
- Authors
- Montoliu-Gaya, L., Benedet, A. L., Tissot, C., Vrillon, A., Ashton, N. J., Brum, W. S., Lantero-Rodriguez, J., Stevenson, J., Nilsson, J., Sauer, M., Rahmouni, N., Brinkmalm, G., Lussier, F. Z., Pascoal, T. A., Skoog, I., Kern, S., Zetterberg, H., Paquet, C., Gobom, J., Rosa-Neto, P., & Blennow, K.
- Affiliations
- University of Gothenburg (SE)
- Centre intégré universitaire de santé et de services sociaux de l'Ouest-de-l’Île-de-Montréal (CA)
- Inserm (FR)
- King's College London (GB)
- Universidade Federal do Rio Grande do Sul (BR)
- University of Pittsburgh (US)
- Sahlgrenska University Hospital (SE)
- University of Wisconsin–Madison (US)
- Corresponding author
- Blennow, Kaj
- ORCID
- Montoliu-Gaya, Laia
- Benedet, Andréa L.
- Tissot, Cécile
- Vrillon, Agathe
- Ashton, Nicholas J.
- Brum, Wagner S.
- Lantero-Rodriguez, Juan
- Stevenson, Jenna
- Nilsson, Johanna
- Rahmouni, Nesrine
- Brinkmalm, Gunnar
- Lussier, Firoza Z.
- Pascoal, Tharick A.
- Skoog, Ingmar
- Kern, Silke
- Zetterberg, Henrik
- Paquet, Claire
- Gobom, Johan
- Rosa-Neto, Pedro
- Blennow, Kaj
- Venue
- Nature Aging
- Published
- 2023-04-27
- Volume
- 3
- Issue
- 6
- Pages
- 661-669
- ISSN
- 2662-8465 (ISSN-L)
- PMC
- PMC10275761
- OpenAlex
- W4367321693
- Cited by
- 122
- References
- 41
- Citations by year
- 2026: 26 · 2025: 51 · 2024: 37 · 2023: 8
- FWCI
- 21.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Aging (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion, cc-by)
- Funders
- BrightFocus Foundation (A2022015F)
- Familjen Erling-Perssons Stiftelse (FO2022-0270, ALFGBG-71320, ADSF-21-831377-C, #ADSF-21-831381-C, 860197, 101053962, #201809-2016862, ADSF-21-831376-C)
- Gun och Bertil Stohnes Stiftelse
- Stiftelsen för Gamla Tjänarinnor (2020-00959, FO2022‐0270, 860197)
- Fondation Vaincre Alzheimer
- European Commission (-71320, ADSF-21-831377-C, FO2022-0270, ADSF-21-831381-C, 201809-2016862, 101,053,962, HORIZON2020, ALFGBG-71320, 860197, ADSF-21-831376-C)
- Hjärnfonden (#FO2022-0270, 860197)
- Vetenskapsrådet (FO2022-0270, ADSF-21-831377-C, #101053962, 860197, ADSF-21-831376-C, ALFGBG‐71320, 201809-2016862, 02532, 2018-, #ADSF-21-831381-C, 2018-02532)
- Göteborgs Universitet
- Alzheimerfonden (AF‐968621)
- Demensfonden
- Olav Thon Stiftelsen
- HORIZON EUROPE Framework Programme (101053962, 860197)
- National Institute on Aging (R01AG068398)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
- Keywords
- phosphorylated tau, plasma tau, Alzheimer's disease, blood biomarkers, tau phosphorylation sites, p-tau217, p-tau231, amyloid, tau pathology, immunoprecipitation mass spectrometry, disease staging
- MeSH terms
- Alzheimer Disease, Brain, Humans, Biomarkers, Amyloid beta-Peptides, tau Proteins, Amyloidogenic Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies. https://app.cochat.ai/papers/10.1038/s43587-023-00405-1
- The paper
- Montoliu-Gaya, L., Benedet, A. L., Tissot, C., Vrillon, A., Ashton, N. J., Brum, W. S., Lantero-Rodriguez, J., Stevenson, J., Nilsson, J., Sauer, M., Rahmouni, N., Brinkmalm, G., Lussier, F. Z., Pascoal, T. A., Skoog, I., Kern, S., Zetterberg, H., Paquet, C., Gobom, J., . . . Blennow, K. (2023). Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies. Nature Aging. https://doi.org/10.1038/s43587-023-00405-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.